Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. John Mascarenhas
Icahn School of Medicine at Mount Sinai
New York, NY, USA
John Mascarenhas is a professor of medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY, USA, a member of the Tisch Cancer Institute, the director of the Adult Leukemia Program and leader of clinical research within the Myeloproliferative Disorders Research Program at ISMMS. read more
As a clinical investigator in malignant haematology with a focus on translational research in myeloproliferative neoplasms (MPN), Prof. Mascarenhas is primarily responsible for the clinical trials portion of the Myeloproliferative Disorders Research Program at ISMMS. Prof. Mascarenhas is also the principal investigator (PI) of the clinical trials project within the National Cancer Institute sponsored by the Myeloproliferative Neoplasm Research Consortium. He has served as a PI or study chair of multiple investigator-initiated and industry-sponsored early- and late-phase clinical trials evaluating innovative approaches to the treatment of MPN and secondary leukaemia.
Prof. John Mascarenhas discloses Advisory board or panel fees from AbbVie, Bristol Myers Squibb, Celgene, CTI BioPharma, Galecto Biotech, Geron Corporation, GlaxoSmithKline, Imago BioSciences, Inc., Incyte Corporation, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, Pfizer, PharmaEssentia and Sierra Oncology. Grants/research support from AbbVie, Bristol Myers Squibb, Geron Corporation, Incyte Corporation, Kartos Therapeutics, Novartis and PharmaEssentia.
Dr Raajit Rampal
Memorial Sloan Kettering Cancer Center
New York, NY, USA
Raajit Rampal is a haematologic oncologist and associate member at the Memorial Sloan Kettering Cancer Center, and clinical director of the leukaemia service, based in New York, NY, USA. read more
Dr Rampal is a physician-scientist with an active laboratory, and leads the clinical myeloproliferative neoplasms (MPN) programme at the Memorial Sloan Kettering Cancer Center. He received his MD and PhD at Stony Brook University, New York and completed his haematology/oncology fellowship at the Memorial Sloan Kettering Cancer Center, with post-doctoral training in the lab of Ross Levine. The focus of Dr Rampal’s research has been to utilize genetic insights from primary patient samples to elucidate mechanisms of pathogenesis in acute myeloid leukaemia and the Philadelphia chromosome-negative MPN, and to develop novel therapeutic strategies for these diseases.
Dr Raajit Rampal discloses Advisory board or panel fees from AbbVie, Galecto Biotech, GlaxoSmithKline, Incyte Corporation, Kartos Therapeutics, Karyopharm Therapeutics, PharmaEssentia and SDP Pharma. Consultancy fees from Bristol Myers Squibb/Celgene, CTI BioPharma, MorphoSys, Servier, Stemline Therapeutics Inc. and Zentalis Pharmaceuticals. Grants/research support from Constellation Pharmaceuticals, Ryvu Therapeutics, Stemline Therapeutics Inc. and Zentalis Pharmaceuticals.
